Human members of the solute carrier 1 (SLC1) family of transporters take up excitatory neurotransmitters in the brain and amino acids in peripheral organs. Dysregulation of their functions is associated to neurodegenerative disorders and cancer. Here we present the first crystal structures of a thermostabilized human SLC1 transporter, the excitatory amino acid transporter 1 (EAAT1), with and without allosteric and competitive inhibitors bound. The structures show novel architectural features of the human transporters, including intra-and extracellular domains with potential roles in transport function, as well as regulation by lipids and post-translational modifications. The coordination of the inhibitor in the structures and the change in the transporter dynamics measured by hydrogen-deuterium exchange mass spectrometry, reveal an allosteric mechanism of inhibition, whereby the transporter is locked in the outward-facing states of the transport cycle. Our results provide unprecedented insights into the molecular mechanisms of function and pharmacology of human SLC1 transporters.
together, these structural data can prove useful for the design of novel allosteric compounds with improved selectivity for both EAATs and ASCTs.
EAAT1 engineering and crystallization
Purified wild-type EAAT1 lacks transport activity upon reconstitution in synthetic liposomes (Fig. 1a) , and was recalcitrant to crystallization. To obtain functional protein suitable for crystallographic studies, we engineered a thermostable EAAT1, called EAAT cryst that shares an overall ~75% sequence identity with the wild type, and up to ~90% identity at the Cterminal core of the protein (Extended Data Fig. 1; Methods) , where the transported substrate and coupled ions are expected to bind24-29. Indeed, purified EAAT1 cryst reconstituted in liposomes showed robust glutamate uptake that depends on opposite gradients of sodium and potassium ions across the bilayer (Fig. 1a and Extended Data Fig.  2a) , and was inhibited by the EAAT1-selective compound UCPH 101 (IC 50 of 4.5±0.3 μM, Hill coefficient 0.92±0.07) (Fig. 1b) . These data show that the transport mechanism and pharmacological selectivity are conserved in EAAT1 cryst .
Notably, EAAT1 cryst crystallized in the presence of UCPH 101 , and we solved its inhibitorbound structure (see Methods and Extended Data Table 1 ), but it was refractory to crystallization in the absence of UCPH 101. To overcome this, we introduced M231I and F235I mutations in the inhibitor-binding pocket (Extended Data Fig. 1) , and solved the crystal structures of the so-called EAAT1 cryst-II both in the presence and absence of the inhibitor (Extended Data Table 1 ). Purified EAAT1 cryst-II also showed robust sodium-and potassium-dependent glutamate uptake, while the UCPH 101 IC 50 increased >30-fold (>131±38 μM, Hill coefficient 0.92±0.0; Fig. 1a,b) , as expected due to the mutations in the inhibitor binding pocket (see below).
Domain organization
The structure of EAAT1 cryst shows a symmetric homotrimer in a substrate-and UCPH 101 -bound outward-facing conformation ( Fig. 1c-e) with an overall GltPh-like fold21,22 (Extended Data Fig. 3 ). Each monomer is composed of two domains: a scaffold domain (ScaD), including transmembrane helices TM1-2 and TM4-5; and a transport domain (TranD), including TM3, TM6-8 and re-entrant helical loops 1-2 (HP1-2; Fig. 1f ). The three ScaDs form a compact central structure with a propeller-like shape that ensures the trimeric form of the transporter and anchors it to the membrane (Extended Data Fig. 4 ). The three TranDs are more peripheral and localize between the blades of the propeller, making protein contacts exclusively with the ScaDs of their own monomer. The TranD-ScaD interface buries ~3,500 Å 2 , including a conserved salt bridge between E256 and K364, through interactions of residues in the cytoplasmic parts of HP1, TM7, and TM3 (TranD), and TM2, TM4c, and TM5 (ScaD). On the extracellular side, additional contacts occurred between residues in HP2 and TM4 that are well conserved among human transporters (Extended Data Fig. 5 ).
Substrate and ion translocation in SLC1 transporters is thought to occur through large rigidbody movements of the TranD, relative to the static ScaD, that move the cargo in an elevator-like fashion across the membrane22,30. Thus, during the isomerization to the inward-facing state the TranD-ScaD interface changes drastically on the TranD side, and the novel features observed at this interface in EAAT1 cryst might influence the distinct TranD dynamics in human SLC1 proteins.
Transport domain
One of the most remarkable architectural features of the EAAT1 cryst TranD is in TM8, where there are deletions and insertions compared to prokaryotic homologs ( Fig. 2 and Extended Data Fig. 3 ). In EAAT1 cryst , TM8 can be divided into extracellular (TM8a), transmembrane (TM8b), and cytoplasmic (TM8c) helices. The loop connecting TM8a and HP2 is six residues shorter in human SLC1 transporters, and brings their extracellular ends in close contact through hydrogen bonding and hydrophobic interactions (Fig. 2) . HP2 is a dynamic element that controls the access of substrate and ions to their binding sites in the TranD24,31-33, and its interactions with TM8b likely play an important role in determining HP2 movements. Consistently, single-cysteine mutations at positions along TM8a in EAAT134, and in a rodent EAAT2 ortholog35 impaired glutamate transport, highlighting the significance of this extracellular region for function.
In TM8b, we found strong electron density for the substrate (L-aspartate) and one of the sodium ions (Na2) in similar sites than in the structures of prokaryotic homologs24,29 ( Fig.  2) . Remarkably, the carboxylate group of D456 (TM8b), which coordinates the α-amino group of the substrate, is also at hydrogen bond distance with the hydroxyl group of S343 (HP1). Moreover, the guanidinium group of R457 (TM8b) engages in hydrogen bonding with HP1 residue G341, and possibly L340 and T342 that point their backbone carbonyl oxygen atoms towards TM8b. Residues S343 and R457 are well conserved in human SLC1 transporters, and substitutions at equivalent positions in EAAT1 (S363 and R477)36, and EAAT3 (R445)37 inactivate transport. In addition, the loss-of-function mutation R445W in EAAT3, equivalent to R457 in EAAT1 cryst , causes human dicarboxylic aminoaciduria38. Overall, the functional studies and our structural data converge to suggest that interactions between conserved human residues at HP1 and TM8b are important to the correct folding and function of the transporters.
On the cytoplasmic side, TM8 extends beyond the membrane through a hydrophilic helix (TM8c) that makes contact with TM3 and TM7a (Fig. 2) . EAAT2 deletion mutants in this region have a deleterious effect on transport function and membrane trafficking39. Accordingly, an EAAT1 deletion in TM8c decreased glutamate uptake rate by ~2-fold (Extended Data Fig. 2b) . Indeed, the functional data and the TM8c amino acid conservation among EAATs underscore the pivotal role of this novel structural motif in protein folding and transport kinetics.
Scaffold domain
The ScaD contains highly divergent regions, especially in TM4 (Extended Data Fig. 1 ), where EAAT1 cryst shows several unique architectural features. On the extracellular side, TM4a forms inter-and intra-monomeric contacts with TM2 and HP2, respectively.
Moreover, an amino acid insertion between TM4b and TM4c (TM4b-c loop) that appeared during the evolution of eukaryotic transporters protrudes into the central vestibule of the EAAT1 cryst trimer (Fig. 3a and Extended Data Fig. 4) . The TM4b-c loop forms the center of the propeller, and makes extensive contacts within and between protomers. Although, we could not model the outermost residues in the TM4b-c loop (Y200-V210), they are expected to each out to the bulk solvent exposing an N-glycosylation site (N204). Notably, all human SLC1 transporters contain predicted N-glycosylation sites in the TM4b-c loop, suggesting a conserved role of this loop in the posttranslational processing of these proteins.
On the cytoplasmic side, TM1 bends and re-orients its N-terminal part (TM1a) nearly parallel to the membrane plane, which forms the tips of the propeller's blades (Fig. 1c and Fig. 3b) . The position and amphipathic nature of TM1a suggests that it somehow interacts with the inner leaflet of the membrane. Consistently, in the hydrophobic crevice between TM1a and HP1a, we observe strong non-protein electron density that likely corresponds to bound detergent or lipid molecules (Fig. 3b) . Interestingly, a second hydrophobic crevice between the extracellular part of TM4 and HP2, also shows strong non-protein electron density (Fig. 3a) . A similar crevice was also noted in a substrate-bound structure of GltPh21.
Lipids strongly regulate SLC1 transport function40-44, and those hydrophobic crevices at the interface between the TranD and ScaD, where large conformational changes occur during substrate translocation, might constitute sites for lipid regulation of transport function.
UCPH 101 binding site
The structure of EAAT1 cryst showed strong electron density for UCPH 101 in a hydrophobic pocket between TM3, TM7 and TM4c at the TranD-ScaD interface, where the compound extends the interface by ~ 500 Å 2 (Fig. 1d,e and Fig. 4a,b) . The chromene skeleton, the parental group of the UCPH series of compounds, is buried deeply in the domains interface, and coordinated by a direct ring-stacking interaction with F369 (TM7a), as well as hydrophobic interactions with G120 (TM3), V373 (TM7a) and M231 (TM4c) (Fig. 4b) . In addition, the amine group of UCPH 101 forms a hydrogen bond with the main-chain carbonyl of F369, while its carbonitrile group interacts with Y127 (TM3). The methoxy-phenyl and naphthalene groups appear partially facing the hydrocarbon core of the membrane. Yet, the former establishes hydrophobic interactions with V124 (TM3), V373 and M231, while the latter is mainly coordinated by F235 (TM4c). The majority of the above-mentioned residues are important for UCPH 101 transport inhibition of an EAAT1 rodent ortholog20. Furthermore, the M231I-F235I double mutant (EAAT1 cryst-II ) showed >30-fold increase in UCPH 101 IC 50 compared to EAAT1 cryst in proteo-liposomes (Fig. 1b) . Hence, there is an excellent agreement between the crystallographic and functional data.
Several mechanistically-relevant observations can be made regarding the UCPH 101 binding pocket in EAAT1 cryst : i) it is over 15 Å away from the substrate and sodium binding sites, suggesting that UCPH 101 does not preclude extracellular substrate binding; ii) it faces the inner leaflet of the membrane, implying that UCPH 101 accesses its binding site from the lipidic, and not the aqueous phase, when applied extracellularly; iii) it is fully contained in a Fig. 6b ). This conformational change shows the EAAT1 cryst TranD is able to move as rigid bodies relative to the ScaD, and highlights the importance of such movements for the function of the human transporters, as it has been shown for GltPh22,23.
The structural changes observed in the UCPH 101 -unbound structure unambiguously demonstrate that the assigned binding pocket of UCPH 101 is correct, and that within the restricted environment of the crystal lattice, UCPH 101 induces both local and global conformational changes of the transporter that optimize its coordination in an outwardfacing state.
Transport domain dynamics
The coordination of UCPH 101 in the crystal structures, wedged in the TranD-ScaD interface, as well as the effect of the M231I-F235I mutations on its potency strongly suggest that UCPH 101 inhibits transport by trapping the transporter in an outward-facing state. Consistently, the rigid-body movements of the TranD to isomerize the transporter into the inward-facing state would separate the coordinating residues in the TranD from those in the ScaD, and disrupt the UCPH 101 coordination. Hence, under equilibrium conditions where the transporters are sampling outward-and inward-facing states, the expected effect of UCPH 101 binding is to shift the equilibrium in favor of the outward-facing state.
To gain insights into the effects of UCPH 101 binding to the transporters at equilibrium, we probed the detergent solubilized EAAT1 cryst by hydrogen-deuterium exchange mass spectrometry (HDX-MS). HDX-MS measures the rate of exchange of backbone amide hydrogen atoms that depends on solvent accessibility and hydrogen bonding, and provides valuable information on the dynamics and conformational changes of proteins45,46.
We compared the HDX behavior of the EAAT1 cryst in the presence and absence of UCPH 101 . Overall, the deuterium uptake pattern of EAAT1 cryst shows dynamic structural elements in both the TranD and ScaD (Extended Data Fig. 7-8 ), and reveals the unstructured and solvent-exposed nature of several regions that were not resolved in the crystal structures, including the TM3-TM4a (peptide 153-173) and TM4b-c (peptide 200-208) loops, as well as the N-(peptide 1-28) and C-termini (peptides 490-522) (Extended Data Fig. 9 ).
Binding of UCPH 101 significantly decreased deuterium uptake in several areas of the TranD including its binding pocket (residues 112-123 and 370-374), and the surrounding area (residues 354-369), while it left the uptake in the ScaD unchanged (Fig. 5a ). It also decreased deuterium uptake in distant residues (336-349 and 420-430) at the tips of HP1 and HP2 involved in substrate coordination and occlusion, suggesting that UCPH 101 induces conformational changes in the transporter upon binding. To gain insights into the nature of those conformational changes, we first compared the TranD areas in which UCPH 101 decreased uptake with those buried at the interface with ScaD in the EAAT1 cryst structure, and found that they correlate remarkably well ( Fig. 5a -c). Second, we built a model of the EAAT1 cryst inward-facing state, based on a recently solved structure of GltPh23, to assess the changes in solvent accessibility in a possible transition between inward-and outwardfacing states (Fig. 5c,d ). Indeed, the comparison between the structure and the model shows that the UCPH 101 -modified areas detected by HDX-MS transit as rigid bodies from being solvent-exposed, in the inward-facing state, to buried at the TranD-ScaD interface, in the outward-facing state. Such conformational change is expected to decrease the dynamics of alpha helices and/or the solvent accessibility of the loops in the UCPH 101 -modified areas and thus, is consistent with the observed decrease in deuterium uptake. Overall, the UCPH 101 -TBOA TFB -bound structure is similar to that of the UCPH 101 -bound state, with the exception of HP2 that adopts an "open" conformation and packs against the TM4b-c loop, disrupting the coordination of the Na2 (Fig. 6a,b) . These conformational changes resemble those previously observed in the structure of the GltPh-TBOA complex, and are in excellent agreement with the proposed competitive inhibitory mechanism of TBOA-like compounds24.
In the substrate-binding site, we observed excess electron density for the bulky TBOA TFB (Fig. 6c) , but due to lack of resolution, we were not able to unambiguously orient the compound. Hence, we initially positioned the TBOA moiety of TBOA TFB using the TBOAbound GltPh structure as a guide. After crystallographic refinement, the additional benzoylamino and trifluoromethyl groups of TBOA TFB in EAAT1 cryst localized in a hydrophobic cavity mainly formed by residues in HP1b and TM7a, and possibly by residues in TM2 and TM4c, likely explaining the observed ~1500-fold increase in EAAT1 inhibitory potency over TBOA47.
Indeed, in the TBOA TFB -bound structure UCPH 101 is bound with an identical coordination than in the substrate-bound state. Therefore, the EAAT1 cryst structures show that UCPH 101 binding at its allosteric site does not preclude the movements of HP2 involved in substrate and sodium binding from the extracellular solution.
Inhibitory mechanisms of EAAT1
The structural and functional EAAT1 cryst data reveal new architectural features of human SLC1 transporters, and their first molecular mechanism of allosteric inhibition. UCPH 101 binding "glues" the TranD to the ScaD in the outward-facing states, and precludes substrate translocation, but not binding from the extracellular solution (Fig. 7) . Non-conserved residues in the ScaD determined UCPH 101 selectivity for EAAT1. This inhibitory mechanism contrasts with that of substrate-analog inhibitors like TBOA. The binding pocket of TBOA-like compounds overlaps with the conserved substrate binding site24, explaining their lack of selectivity among glutamate transporters and the inhibition of substrate binding observed on either side of the membrane48,49.
The unique inhibitory mechanism of UCPH 101 makes it an extremely valuable pharmacological tool to study the conformational changes that EAAT1 undergoes upon substrate and ion binding. Remarkably, the UCPH 101 allosteric binding site highlights a cavity that can facilitate the design of selective compounds for other human SLC1 transporters, and possibly the long-sought positive modulators of glutamate uptake.
Methods

Construct optimization
We used fluorescence-detection size-exclusion chromatography (FSEC)50 to screen solubilization conditions and EAAT1 variants fused to enhanced green fluorescent protein (eGFP). EAAT1 N-terminal fusions solubilized in dodecanoyl sucrose (DDS, Anatrace) were found to have good solubility and mono-dispersity by FSEC in clear lysates. However, EAAT1 looses its transport activity and chromatographic monodispersity upon purification.
To increase its stability, we used consensus mutagenesis51, and screened EAAT1 variants with different consensus mutations in the predicted transmembrane helices by FSEC. The apparent melting temperature (Tm) of the most stable EAAT1 construct was >20 °C over that of the wild-type EAAT1, but the mutated transporter was still refractory to crystallization. We reasoned that the divergent extracellular region between TM3-4c could interfere with crystallization, and changed it for the equivalent region in ASCT2, the shortest one among human SLC1 members (Extended Data Fig.1 ). In addition, we mutated the two predicted N-glycosylation sites of the transporter (N155T and N204T mutations) to further improve crystallizability.
Expression and purification
All constructs were introduced into pcDNA3.1(+) (Invitrogen) with N-terminal Strep-tag II affinity tag followed by eGFP and PreScission protease cleavage site, and expressed in HEK293F cells (ATCC, mycoplasma test negative) grown in Excell293 medium (Sigma) and supplemented with 4mM L-glutamine (Sigma) and 5µg/ml Phenol red (Sigma-Aldrich) to densities of 2.5 x 10 6 cells ml -1 . Cells were transiently transfected in Freestyle293 medium (Invitrogen) using poly-ethylenimine (PEI) (Polysciences) at a density of 2.5 x 10 6 cells ml -1 , diluted with an equivalent volume of Excell293 6 hours post-transfection, and treated with 2.2 mM valproic acid (Sigma) 12 hours after dilution of the cultures. Cells were collected at ~48 h post-transfection.
Initial screens of constructs and detergent solubilization buffers were done in small-scale Membranes were washed once with the above-mentioned buffer and finally homogenized with a douncer in a buffer containing 50 mM HEPES/Tris-base, pH 7.4, 200 mM NaCl, 1 mM L-asp, 1 mM EDTA, 1 mM TCEP, and 10% Glycerol, snap-frozen in liquid N 2 and stored at -80°C at 0.5 g of membranes ml -1 .
Membrane solubilization was done by thawing out and supplementing the membrane homogenate with 2% DDS, 0.4% CHS, and 25 μM UCPH 101 (Abcam). After 1-hour incubation, the insoluble material was removed by ultracentrifugation (186,000g for 1 h), and Strep-Tactin sepharose resin (GE Healthcare) was added to the supernatant and rotated for 2 h. Resin was washed with 25 column volumes of 50 mM HEPES/Tris-base, pH 7.4, 200 mM NaCl, 1 mM L-asp, 1 mM TCEP, 5% Glycerol, 0.05% DDS, 0.01% CHS and 25 μM UCPH 101 , and the protein was eluted with the same buffer supplemented with 2.5 mM D-desthiobiotin.
The eluted eGFP-transporter fusion was concentrated to 1-2 mg ml -1 using 100-kDa cutoff membranes (Millipore), and digested with His-tagged PreScission protease overnight at 4 °C. The protease was removed by reverse Ni-NTA (Qiagen) affinity chromatography, and the flow through containing the transporter was concentrated to 500 μl, ultra-centrifuged (86,900 g, 20 min), and applied to a Superose 6 10/300 gel filtration column (GE Healthcare) equilibrated with 50 mM HEPES/Tris-base, pH 7.4, 200 mM NaCl, 1 mM Lasp, 1 mM TCEP, 5% Glycerol, 0.25% decanoyl sucrose (DS, Sigma), 0.05% CHS and 100 μM UCPH 101 . To obtain the UCPH 101 unbound structure, the protocol was identical, but the allosteric inhibitor was omitted from all buffers. To obtain the UCPH 101 -TBOA TFB bound structure, the protein sample was supplemented with 3 mM TBOA TFB (Tocris) before the injection in the gel filtration column equilibrated with 50 mM HEPES/Tris-base, pH 7.4, 200 mM NaCl, 1 mM TCEP, 5% Glycerol, 0.25% decanoyl sucrose (DS, Sigma), 0.05% CHS, 300 μM TBOA TFB and 100 μM UCPH 101 .
Protein samples after the solubilization step were kept on ice or at 4 °C at all times.
Crystallization and structure determination
Purified protein was concentrated to 3.5-4.0 mg ml -1 and 1 mM UCPH 101 was added in experiments with the inhibitor-bound transporters. Initial vapor diffusion crystallization screens were done by mixing 300 nl of protein and reservoir solution in sitting drops, dispensed by a Mosquito robot (TTP labtech) in 96-well Greiner plates. The purified transporters form three-dimensional crystals in several conditions containing low molecular weight polyethylene glycols. The best-diffracting crystals were obtained after manual optimization using 1.6 μl hanging drops at 4 °C, obtained by mixing equal volumes of protein supplemented with 0.2% n-Octyl-b-D-glucopyranoside (BOG, Anatrace) and 0.04% CHS, and reservoir solutions containing 100 mM Tris, pH 8.2, 50 mM CaCl 2 , 50 mM BaCl 2 , and 28-30% PEG 400. Crystals appeared after 24-48 h and reached their maximum size after a week. Crystals were flash-frozen in liquid nitrogen before X-ray diffraction data collection without any further cryo protection.
X-ray diffraction data were collected at beamlines PROXIMA-1 at the SOLEIL synchrotron (St Aubin, France) and at beamlines at the European Synchrotron Radiation Facility (Grenoble, France). In general, 2-3 data sets from single crystals were collected, and indexed, integrated, scaled and merged using XDS package52. Due to the anisotropic nature of the diffraction data, the DEBYE and STARANISO programs were applied to scale it using the STARANISO server (http://staraniso.globalphasing.org/). The software performs an anisotropic cut-off of merged intensity data with a Bayesian estimation of the structure amplitudes, and applies an anisotropic correction to the data. Table 1 shows the refinement statistics for the full sets of reflections truncated at the best high-resolution along h, k or l axis, values given by AIMLESS53, before the anisotropic corrections computed by the STARANISO software. The corrected anisotropic amplitudes were then used for molecular replacement in PHASER54, using the scaffold and transport domains of GltPh (PDB code 2NWL) as independent search models. The initial electron density maps were clearly interpretable, and the final model was obtained through rounds of manual building in COOT55 and refinement in Buster56, until reaching good crystallographic statistics and stereochemistry (Extended Data Table 1 ). The model contains one EAAT1 cryst monomer per asymmetric unit and most of the EAAT1 cryst polypeptide (residues 37-487), with the exception of some residues in the extracellular loops between TM3-4a, TM4b-4c, TM5-6 and TM7b-HP2a. Sequence assignment was aided by anomalous difference Fourier maps from diffraction data collected with low energy X-rays (1.77 Å) to highlight the sulfur atoms of methionine and cysteine residues (Extended Data Fig. 6c,d ). EAAT1 cryst-II , as well as the EAAT1 cryst UCPH 101 -TBOA TFB bound structures were solved by the same approach above mentioned, but using the EAAT1 cryst TranD and ScaD as independent search models for molecular replacement.
The stereochemical properties of the final models were analyzed with the Molprobity server (http://molprobity.biochem.duke.edu/). At least 95% of the residues in all models are in the Ramachandran favored region. Protein interfaces were analyzed with the PISA server (http:// www.ebi.ac.uk/msd-srv/prot_int/pistart.html). Structural alignments were done with Superpose in the CCP4 suite. All structural figures were prepared with PyMOL Molecualr Graphics System, Schrodinger, LLC.
Radioactive substrate transport assays
Unilamellar liposomes were made at 9:1 molar ratio of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (Avanti Polar Lipids) and CHS, in a buffer containing 50 mM HEPES/Trisbase, pH 7.4, 200 mM NaCl and 1 mM L-asp. The transporters were purified as described above, but excluding the reverse chromatography step after protease cleavage, and using a Superose 6 10/300 column equilibrated with 50 mM HEPES/Tris-base, pH 7.4, 200 mM NaCl, 1 mM L-asp, 0.5 mM TCEP, 0.0632% DDS, 0.01264% CHS, and 5% glycerol.
To reconstitute the protein, liposomes were first mixed with DDS at a 1:2 (w/w) lipid-todetergent ratio for 1 h, and then the purified transporters were added at a 1:40 (w/w) proteinto-lipid ratio. Detergent removal was done at 4° C using SM-2 biobeads (BioRad) at 100 mg ml -1 . The internal solution of the liposomes was exchanged using 10 freeze-thaw cycles in the appropriate buffer. After extrusion through 400-nm polycarbonate membranes (Avanti Polar Lipids), the proteoliposomes were concentrated by ultracentrifugation (150,000 g for 30 min at 4°C) and resuspended at 20 mg of lipids ml -1 , for immediate use.
Substrate transport was assayed at 37°C. The uptake reaction was initiated by diluting the proteo-liposomes 10-fold into a buffer containing 50 mM HEPES/Tris-base, pH 7.4, 200 mM NaCl, 50 µM L-glutamate, and 5 µM [ 14 C]-L-glutamate (PerkinElmer), and 2.5% glycerol. After 30 min, 200-µl aliquots were diluted 5-fold into ice-cold quench buffer (50 mM HEPES/Tris-base, pH 7.4, 200 mM ChCl, and 2.5% glycerol), followed by immediate filtration and wash on nitrocellulose 0.22-µm filters (Millipore). Radioactivity was quantified by liquid scintillation using a Tri-Carb 3110TR counter (PerkinElmer). For the UCPH 101 titrations, proteo-liposomes were both pre-incubated for 20 min at room temperature, and assayed in the presence of UCPH 101 . Background radioactivity was estimated from protein-free liposomes, and subtracted from the uptake data. Data was fitted to a Hill equation of the form:
Where F ∞ is the final level of inhibition, ΔF ∞ is the final amplitude of the UCPH 101 effect, and n is the Hill coefficient.
To titrate the rate of L-glutamate transport by EAAT1 cryst , proteo-liposomes were assayed in the presence of 0, 5, 50 or 200 μM L-glutamate supplemented with 1, 5, 5, or 5 μM [ 14 C]-Lglutamate, respectively. At each substrate concentration, the initial rate of transport was calculated by a linear fit to 120 s and 180 s uptake measurements with origin fixed at zero. Background radioactivity was estimated from protein-free liposomes, and subtracted from the uptake data.
For the cell-based transport uptake, cells were collected 36 h post-transfection, and washed three times and resuspended at a density of 50 x 10 6 cells ml -1 in 11 mM HEPES/Tris-base, pH 7.4, 140 mM ChCl, 4.7 mM KCl, 2.5 mM CaCl 2 , 1.2 mM MgCl 2 , and 10 mM Dglucose, for immediate use. The uptake assay was performed similarly to the one described for the proteo-liposomes, but using a reaction buffer containing 11 mM HEPES/Tris-base, pH 7.4, 140 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl 2 , 1.2 mM MgCl 2 , 10 mM D-glucose, 50 µM L-glutamate, and 5 µM [ 14 C]-L-glutamate, and 0.8-µm nitrocellulose filters. Background radioactivity was estimated from cells transfected with empty vector, and subtracted from the uptake data.
Hydrogen-deuterium exchange mass spectrometry
HDX-MS experiments were performed with transporters purified as described in the proteoliposome section, and using a Superose 6 5/150 gel filtration column equilibrated with 50 mM HEPES/Tris-base, 200 mM NaCl, pH7.4, 1 mM L-asp, 0.5 mM TCEP, 0.0632% DDS, 0.01264% CHS, and 5% glycerol.
The purified EAAT1 cryst was incubated in ice for 30 min with 2.2% DMSO at a monomer concentration of 5.2 µM, in the presence and absence of 102 µM UCPH 101 , respectively. Prior to labeling, 10 µL of the unbound and UCPH 101 -bound EAAT1 cryst solution was equilibrated for 10 min at room temperature. Deuterium exchange was initiated by adding 40 µL of D 2 O buffer (50 mM HEPES, pD 7.3, 200 mM NaCl, 1 mM L-asp, 5% glycerol, 0.0632% DDS, 0.01264% CHS, 0.5 mM TCEP) supplemented or not with 101.2 µM UCPH 101 . Assuming that the K D and IC 50 values of UCPH 101 are similar, ~96% of the transporters would remain bound during deuterium labeling. Aliquots of 10.4 pmols of protein were removed at defined deuterium exchange time points (from 10 sec to 60 min) and quenched upon mixing with an ice-cold acidic solution (0.75% formic acid, 5% glycerol) to decrease the pH to 2.6. Quenched samples were immediately snap-frozen in liquid N 2 and stored at -80°C until analysis.
Prior to mass analysis, quenched samples were rapidly thawed and immediately injected into a cooled nanoACQUITY UPLC HDX system (Waters corp.) maintained at 0°C. 8.6-pmol protein samples were on-line digested for 2 min at 20 °C using an in-house packed immobilized pepsin cartridge (2.0 x 20 mm, 66 µL bed volume). The resulting peptides were trapped and desalted onto a C18 Trap column (VanGuard BEH 1.7 µm, 2.1 x 5 mm, Waters corp.) at a flow rate of 100 µL/min of 0.15% formic acid, and then separated in 10 min by a linear gradient of acetonitrile from 5 to 40% at 40 µL/min using an ACQUITY UPLC™ BEH C18 analytical column (1.7 µm, 1 x 100 mm, Waters corp.). After each run, the pepsin cartridge was manually cleaned with two consecutive washes of 1% formic acid, 5% acetonitrile, 1.5 M guanidinium chloride, pH 2.5. Blank injections were performed between each run to confirm the absence of carry-over.
Mass spectra were acquired in resolution and positive mode on a Synapt G2-Si HDMS mass spectrometer (Waters corp.) equipped with a standard electrospray ionization source, as described previously57. Peptides were identified from undeuterated protein samples acquired in MS E mode by database searching in ProteinLynX Global Server 3.0 (Waters corp.). Each fragmentation spectrum was manually inspected for assignment validation.
Deuterium uptake values were calculated for each peptide using DynamX 3.0 (Waters corp. Amino acid sequences of EAAT1-5, ASCT1-2 and EAAT1 cryst are compared. The boundaries of the α-helices (cylinders) in the TranD (orange) and the ScaD (teal) seen in the EAAT1 cryst structure are shown. In order to confer crystallizability, the region between TM3 and TM4c (arrows) from ASCT2 was transferred to a thermally stabilized EAAT1. To further improve crystal formation in the absence of UPCH 101 , mutations M231I and F235I (circles) were introduced to generate EAAT1 cryst-II . These substitutions are found in EAAT2. Other residues involved in UPCH 101 coordination are more conserved (triangles). Sequences were aligned with Jalview59. One crystal was used to collect diffraction datasets for each structure, except in the EAAT1 cryst UCPH 101 and TFB-TBOA bound structure, where datasets from three crystals were merged.
5% of reflections were used for calculations of R free , except for the EAAT1cryst UCPH101-TBOATFB bound structure where 10% was used due to the lower number of total reflections. Europe PMC Funders Author Manuscripts a, The movement of HP2 (purple) partly exposes the substrate-binding pocket to the solvent and shows a molecule of TBOA TFB (purple sticks) bound to it. UCPH 101 is also observed in this structure (pink sticks). b, The tip of HP2 moves as much as 9.5 Å in the UCPH 101 -TBOA TFB -(purple), compared to the UCPH 101 -substrate bound (orange) structures, placing the carbonyl oxygen of A420 away from Na2 (green sphere). c, Omit map Fo-Fc density for the TBOA TFB molecule is contoured at 2.3σ (black mesh), and some of the residues at Van deer Waals or H-bond distance from the compound are represented as sticks. 
